Status:
COMPLETED
A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin
Lead Sponsor:
AstraZeneca
Conditions:
Pharmakokinetic
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to determine whether the treatment with AZD1981 affect the exposure of Warfarin.
Eligibility Criteria
Inclusion
- Have a body mass index between 19 and 30 kg/m2 and weight at least 65 kg and no more than 100 kg
- Be a non-smoker or ex-smoker who has stopped smoking for \>6 months prior to screening
- Volunteers must be willing to use barrier methods of contraception during study and 3 months after the end of their participation in the study
Exclusion
- Volunteer that is inferred to have an increased sensitivity to warfarin based on genotype of CYP2C9 and VKORC1.
- Any clinically significant disease or disorder
- Any clinically relevant abnormal findings in physical examination
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01199341
Start Date
October 1 2010
End Date
December 1 2010
Last Update
February 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Uppsala, Sweden